Correlation of serum, tumor, and liver serum glycoprotein: N-acetylneuraminic acid transferase activity with growth of the R3230AC mammary tumor in rats and relationship of the serum activity to tumor burden
- PMID: 7427928
Correlation of serum, tumor, and liver serum glycoprotein: N-acetylneuraminic acid transferase activity with growth of the R3230AC mammary tumor in rats and relationship of the serum activity to tumor burden
Abstract
The observation that the activity of sialyltransferase (EC 2.4.99.1; serum glycoprotein:N-acetylneuraminic acid transferase) is often elevated in the serum of cancer patients necessitates an elucidation of the interrelationships of this serum enzyme with host tissues. Accordingly, the activity of this enzyme in serum, tumor, and liver was determined at various times after implantation of the R3230AC mammary carcinoma into Fischer rats. Results from samples obtained at numerous, sequential time points demonstrated that significant elevations in serum sialyltransferase enzyme activity occurred only in animals bearing large tumor burdens, i.e., greater than 20 g, or in animals with tumors present for longer than 21 days. In these tumor-bearing rats, the activity of sialyltransferase increased in liver tissue at 21 to 25 days concurrently with the increase in serum enzyme activity, suggesting that the liver may be a potential source of the serum enzyme. Sialyltransferase activity in tumor tissue was quite variable; the activity increased one week after tumor implantation and remained at the same level thereafter. When tumors were excised, the activity of the serum enzyme returned to control values within four days after surgery, suggesting that the half-life of serum sialyltransferase was two days. Serum enzyme levels were again elevated upon regrowth of the tumor. These results show that the serum sialyltransferase alters its activity in conjunction with changes in tumor burden.
Similar articles
-
Serum and host liver activities of glycosidases and sialyltransferases in animals bearing transplantable tumors.Res Commun Chem Pathol Pharmacol. 1975 Nov;12(3):499-512. Res Commun Chem Pathol Pharmacol. 1975. PMID: 172998
-
Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma.Cancer Res. 1997 Oct 1;57(19):4249-56. Cancer Res. 1997. PMID: 9331085
-
Glycosyltransferases and glycosidases in Morris hepatomas.Cancer Res. 1977 May;37(5):1513-8. Cancer Res. 1977. PMID: 192453
-
Serum-sialyltransferase activity in cancer patients.Klin Wochenschr. 1982 May 3;60(9):445-9. doi: 10.1007/BF01720358. Klin Wochenschr. 1982. PMID: 7045508 Review.
-
The acute phase response to inflammation: the role of monokines in changes in liver glycoproteins and enzymes of glycoprotein metabolism.Comp Biochem Physiol B. 1987;87(1):11-5. doi: 10.1016/0305-0491(87)90463-9. Comp Biochem Physiol B. 1987. PMID: 3111778 Review.
Cited by
-
B cells suppress medullary granulopoiesis by an extracellular glycosylation-dependent mechanism.Elife. 2019 Aug 13;8:e47328. doi: 10.7554/eLife.47328. Elife. 2019. PMID: 31408003 Free PMC article.
-
Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas.Pathol Oncol Res. 2002;8(3):175-82. doi: 10.1007/BF03032391. Epub 2003 Jan 6. Pathol Oncol Res. 2002. PMID: 12515997
-
Post-operative serum sialyltransferase levels and prognosis in breast cancer.Breast Cancer Res Treat. 1983;3(2):225-30. doi: 10.1007/BF01803565. Breast Cancer Res Treat. 1983. PMID: 6616079
-
Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis.J Biol Chem. 2010 Aug 6;285(32):25009-17. doi: 10.1074/jbc.M110.104406. Epub 2010 Jun 7. J Biol Chem. 2010. PMID: 20529847 Free PMC article.
-
Serum sialyl transferase levels in patients with metastatic breast cancer treated by chemotherapy.Br J Cancer. 1982 Aug;46(2):208-12. doi: 10.1038/bjc.1982.185. Br J Cancer. 1982. PMID: 6758827 Free PMC article. Clinical Trial.